Bundesamt für Sicherheit im Gesundheitswesen
BASG

Realignment of the EU-network: Perspectives from the EMA-Management Board and NCAs

21st DGRA Annual Congress
May 23th 2019

Dr. Christa Wirthumer-Hoche
Head of the Austrian Medicines and Medical Devices Agency, Vienna, AUSTRIA
Chair of the EMA Management Board


DAILY EXPRESS
SHE DID IT!
Now it's up to EU
Daily Mail
So what DOES it take to have an 18-year-old's body... in your 40s
SARAH VINE
THERESA TRIUMPH
Brexit goes to the wire
THE TIMES
Attention!
May unites Tories behind fresh talks with Brussels
DAILY Mirror
Brilliant football pullout
MPs' BREXIT GAMBLE
MAY'S DEAL BACK FROM THE DEAD


Brexit: is it worth it?
AND A MEANINGFUL FUTURE FOR THE UK
STAND OF DEFIANCE EUROPEAN MOVEMENT


EXIT from BREXIT
EXIT from BREXIT
www.LibDems.org.uk/join


BREXIT

Realignment of the EU-network

To go or not to go?

Bundesamt für Sicherheit im Gesundheitswesen
BASG

Final Brexit outcome currently still not known

Brexit – timeline:

- UK-participation in EU-election ⇨ Brexit 31/10/19
  - No ratification of the withdrawal agreement until 31/10/19 - "hard Brexit"
  - Ratification of the withdrawal agreement - whenever - withdrawal possible before 31/10/19 (the day after, on the 1st of the following month?), transitional period (according to agreement) until 31/12/19
- Until withdrawal - the UK fully participates in the activities of EMA & EU-network;
  - it continues to participate in all formal meetings and retains its speaking and voting rights.

Preparing realignment

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- Need for the remaining 27 MSs to focus on increasing assessment capacity on the basis of a very good analysis.
- Development of the Business Continuity Plan (BCP)
  - EMA operations
  - Committee operations
  - Supply & availability

- The EU27 Member States and EMA have developed a methodology for the redistribution of the work currently carried out by the
  - UK's Medicines & Healthcare products Regulatory Agency (MHRA) and
  - Veterinary Medicines Directorate (VMD).

Ad hoc Working groups

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- EMA Working Groups on committees' operational preparedness for human and veterinary medicines
- HMA Brexit Task Force (BTF) (decentral – MRP/DCP)

  Chair: Hugo Hurts (MEB) – Co-chair: Thomas Heberer (BVL)

  - Activities of the CMDh & v

    - Allocation of the workload related to human and veterinary medicines across the Network
    - Distribution of the UK medicinal products portfolio
    - Proposal for knowledge transfer
    - Proposals for operational adjustments to streamline the procedures (EMA & NCAs)
    - Analyse the potential impact of Brexit on inspection activites
    - EU signal management

⟹ List of FAQs published by EC/EMA and CMDh

Prepardness

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- **Centrally Authorised Products** – EMA finalised the work in time
- **MR-products** - no centralised approach possible for MRP/DCP
  - CMDh to monitor the RMS-switches from UK to EU-27 (EEA-29)
  - CMDh to publish Q&A to address the situation of the 'Hard Brexit' and to give industry clear guidance for the worst case.
    - use of a MP authorised in UK as a reference MP for a generic/hybrid application after the Brexit
    - can I use a BE study against an authorised UK product after the Brexit, ...
    - can the MAH, batch release, QP, QPPV be located in UK
    - will be a GMP/GCP-Inspection performed by UK still acceptable after the Brexit
    - Medicinal products in MS under Article 126 and authorised in UK
    - not finalised procedures with UK as RMS
    - ...

UK PRODUCTS TO BE REDISTRIBUTED WITHIN THE EEA-29

(Each pharmaceutical form and strength counted separatedly)

(HUMAN MP ONLY: 4210)

RMS switch…	Sep 18	Okt 18	Nov 18	Dec 18	Jan 19	Feb 19	Mrz 19	Apr 19
done/ongoing in CTS (after 01/04/2017)	1136	1299	1451	1740	1962	2408	2662	2864
agreed in Brexit tool	1179	1124	1202	1109	1006	799	716	622
pending	2018	1844	1670	1478	1369	1133	813	724
Redistributable Products	4333	4267	4323	4327	4337	4340	4191	4210





*including
1 (0,0%) recorded 'Requests' and
6 (0,1%) 'Rejections by CMS'
following MAH contact

Tracking on Brexit related RMS changes (online tool)



Monitoring of ongoing procedures with UK as RMS



UK Started DCPs		
Month	Procedures	Products
Jan 2018	19	37
Feb 2018	7	14
Mar 2018	6	11
Apr 2018	13	21
May 2018	7	17
Jun 2018	3	4
Jul 2018	6	12
Aug 2018	4	4
Sep 2018	2	4
Oct 2018	4	8
Nov 2018	6	9
Dec 2018	3	5
Jan 2019	3	8
Feb 2019	3	4
Mar 2019	2	5

Availability of medicinal products in the EU – impact of Brexit on the supply?

Bundesamt für Sicherheit im Gesundheitswesen
BASG

MAs will not automatically become invalid but an active decision by the EMA/NCA is needed i.e. suspension or revocation

Movement of medicines across the UK and EU borders

Bundesamt für Sicherheit im Gesundheitswesen
BASG

Batch testing and release

- Not all companies managed to relocate batch release testing to the EU before March 29th, 2019
- Mitigate risk through a pragmatic solution to maintain supply of medicinal products.

Hard Brexit: what will happen at the borders?

- A “no deal” scenario presents a clear threat of disruption to the supply of medicines throughout the EU (for both CP and MRP/DCP);
  - We have to avoid disruption in the movement of medicines and clinical trial materials across the UK and EU borders to protect the supply to patients in Europe;

Undisrupted supply of UK medicines in the EU

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- EMA/NCAs have undertaken an analysis of the potential supply issues due to the required changes as a consequence of Brexit
- The aim of the analysis was to identify:
  - The manufacturing operations currently located in the UK
  - The type of manufacturing operations affected by Brexit
  - The potential risk of disruption as a number of these operations will need to be relocated to the EEA
- ***Quality control testing Batch Release –*** identified as a major problem
- Possible legal tools to take actions or allow exemptions to avoid shortages of critical products for MS and common approach regarding the possible duration of exemptions.

Availability of Medicinal Products

3rd technical expert seminar on Brexit organized by the EC

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- With regard to the quality control testing there may be objective reasons beyond control of the MAHs that may prevent timely transfer of such testing activities to the EU by the withdrawal date. ;-)
  - Article 20(b) of Directive 2001/83/EC provide that EMA/NCAs may allow importers of medicinal products coming from third countries to have in justifiable cases certain of the controls carried out by third parties.
- In applying these provisions, competent authorities may allow MAHs, for a limited period of time, as a justified case, to rely on quality control testing performed in the UK ("**the exemption**"), under the following conditions
  - exemption is only applicable for existing MAs and no MAs should be granted based on this exemption.

Withdrawal of the UK and EU rules for batch testing of medicinal products

Bundesamt für Sicherheit im Gesundheitswesen
BASG

Exemption – batch release

- specify the batch release site in the EU27.
- confirm that the qualified person established in the EU27 is responsible for the quality control testing site in the UK.
- confirm and set out their precise timetable for transfer of the quality control testing site (by the end of 2019 at the latest).
- specify the period of time and batches (packs and quantities) that are requested to be exempted. This should be strictly restricted to what is necessary.
- batch testing results for those batches from the existing facilities within UK
- samples of those tested batches - available for inspection.

Other activities – post Brexit

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- Inspections
- Clinical trials

Current Status GMP-Inspections post Brexit

Bundesamt für Sicherheit im Gesundheitswesen
BASG

CAPs

- All CAPs are already covered by the system of „Supervisory Authority“
- Every batch on the EU market is certified by a Qualified Person (QP) based in the EU before it can be released for market
- „Supervisory Authority“ is defined as the Competent Authority of the MS, where the site is located where batch certification takes place
- Following this principle, inspection workload resulting from CAPs is already shared amongst the EU27

Current Status GMP-Inspections post Brexit

Bundesamt für Sicherheit im Gesundheitswesen
BASG

Medicinal Products manufactured in UK

- Currently a Position Paper is *under discussion* at the EMA GMDP IWG

- The Position Paper proposes that GMP certificates issued by UK Authorities after the withdrawal date for manufacturing sites located in the UK continue to be used as GMP compliance information and sets out the specific conditions required for this. The measure would be used until further notice, and the IWG will monitor the continued applicability of the conditions set out.

Current Status GMP-Inspections post Brexit

Bundesamt für Sicherheit im Gesundheitswesen
BASG

Medicinal Products manufactured outside UK in 3rd countries

- The Position Paper does not discuss GMP certificates issued by UK Authorities after the withdrawal date for manufacturing sites located in 3rd countries. There were proposals in the IWG Brexit group that a similar position paper should be prepared for sites located in 3rd countries with UK GMPs.

Brexit

Impact on Clinical Trials

Bundesamt für Sicherheit im Gesundheitswesen
BASG

Brexit not only affects the supply of drugs, and ….. but also the important field of clinical research:

- For clinical trials where the sponsor or legal representative of the sponsor is currently still based in the UK, it is necessary to ensure that there is a sponsor or legal representative based in the EU or EEA.
- Companies producing investigational medicines to be used in clinical trials may also need to transfer certain operations from the UK into an EU/EEA Member State, as for approved medicines, to comply with EU law.

Challenges for the EU-Network

EU network strategy 2021 - 2025

Bundesamt für Sicherheit im Gesundheitswesen
BASG

- Current regulatory framework for medicines
  - new technologies
  - scientific developments

  Regulatory framework flexible enough to accommodate the new products developed using the new technologies and scientific developments? EU-Innovation Network
  - new approaches to authorisation and pharmacovigilance or new guidelines in specific areas necessary
  - new expertise and competences in the Network necessary to both regulate and assess these new areas. EU-NTC – cooperation with academia
- Appropriate IT tools necessary
  - Every new piece of EU legislation requires for implementation the establishment of a database, a complex IT system, information system, etc.

Bundesamt für
Sicherheit im
Gesundheitswesen
BASG

DI Dr. Christa Wirthumer-Hoche

Head of the Austrian Medicines and Medical Devices Agency

BASG -
Bundesamt für Sicherheit im Gesundheitswesen

Traisengasse 5
1200 Wien
T +43 (0) 50555-36000

christa.wirthumer-hoche@ages.at
www.basg.gv.at